

Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 

Dated 8 September 2000

The Patent Office

RECEIVED 27 AUG 1999
POSTED 6.00 - 15.00

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P022706GB

2. Patent application number

(The Patent Office will fill in this part)

27 AUG 1999

9920397.8

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Medical Research Council
20 Park Crescent
London
W1N 4AL

Patents ADP number (if you know it)

596001001

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

4. Title of the invention

Method for Coupling Molecules

5. Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001 ✓

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body

Yes

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 27

Claim(s) 6

Abstract 0

Drawing(s) 0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Carpmaels & Ransford
Carpmaels & Ransford

Date

27th August 1999

12. Name and daytime telephone number of person to contact in the United Kingdom

Dr. Paul N. Howard

0171 242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

METHOD FOR COUPLING MOLECULES

The present invention relates to a method for coupling molecules such as peptides and oligonucleotides, as well as synthetic intermediates and coupling agents therefor.

5

Conjugates of, for instance, peptides and oligonucleotides have many potential applications. Recently, a number of peptides have been proposed as carriers of oligonucleotides or DNA into cells. These peptides may be covalently linked to oligonucleotides via an appropriate linker.

10

The conjugation of molecules such as peptides and oligonucleotides requires reliable coupling chemistry which should be widely applicable to conjugates that vary substantially in composition. To date, there have been very few methods available for synthesising conjugates which meet these criteria. Some strategies for coupling molecules such as
15 peptides and oligonucleotides involve synthesis and/or attaching one or both of the coupling components onto a solid support. One of the advantages of carrying out coupling reactions on solid phase is the facile purification of the product. Consequently, the technology is amenable to automated synthesis.

20 Perhaps the most ambitious route to the synthesis of peptide-oligonucleotide conjugates has been the total stepwise solid-phase approach on a single solid support. However, such a route poses serious difficulties, both technically and chemically. Firstly, no automated machine exists which can handle a sufficiently wide range of reagents to carry out the sequential assembly of peptides and oligonucleotides. Secondly, there are severe problems
25 of compatibility in the assembly chemistries, particularly in the choice of protecting groups and deprotection conditions. Such problems have limited this approach to relatively short peptides, the longest reported conjugate produced by such a method being a 13-mer D-peptide of IGF1 coupled to a phosphorothioate 15-mer (Basu *et al.*, Tetrahedron Lett., 36 (1995) 4943).

30

- A more general strategy for peptide-oligonucleotide conjugation is where peptide and oligonucleotide moieties are assembled separately on their own solid supports and are designed to carry a reactive functionality that is released upon full deprotection and cleavage from the support. Following purification, peptide and oligonucleotide parts are
- 5 joined in aqueous or non-aqueous solution through the reactive functionalities. The methods currently available for coupling such functionalised peptides and oligonucleotides are somewhat limited. Bongartz *et al.* (Nucleic Acids Res., 22 (1994) 4681), Vives *et al.* (Tetrahedron Lett., 38(1997) 1183) and Eritja *et al.* (Tetrahedron Lett., 47(1991) 4113) have reported on coupling via formation of a disulfide bond. Harrison *et al.* (Nucleic
- 10 Acids Res., 26(1998) 3136) and Tung *et al.* (Bioconj. Chem., 2 (1991) 464) have reported on coupling of a cysteine peptide with a maleimido oligonucleotide. Arar *et al.* (Bioconj. Chem., 6 (1995) 573) reports on the coupling of a bromoacetyl peptide with a thiol-functionalised oligonucleotide.
- 15 McMinn and Greenberg have reported the non-aqueous conjugation of a partially protected peptide via its carboxyl terminus or as an aryl isocyanate derivative to a 3'-amino functionalised oligonucleotide (McMinn and Greenberg, J. Amer. Chem. Soc., 120 (1998) 3289).
- 20 Some disadvantages of performing the conjugation reaction in aqueous or non-aqueous solution by published procedures are (a) the oligonucleotide often needs to be further functionalised after release from the support, (b) one or both of the coupling components often will need to be purified prior to conjugation, (c) a limitation in the peptide sequence (e.g. need for a cysteine), (d) inefficient conjugation due to secondary structure or poor
- 25 solubility of the peptide or oligonucleotide components, and (e) difficulties in separation of coupling components from the product conjugate, especially when conjugation yields are poor.
- The solid-phase fragment conjugation method involves the retention of one component on
- 30 a solid support during conjugation whilst the other remains in solution. For example Grandas *et al.* have reported the fragment conjugation of a tripeptide as an amido

phosphoramidite derivative to a support bound hexanucleotide (Grandas et al. *Nucleoside and Nucleotides*, 14 (1995) 825). Peyrottes et al. have reported the conjugation of several peptides via the carboxy termini to support bound oligonucleotides which have been 5'-amino functionalised (Peyrottes et al., *Tetrahedron*, 54 (1998) 12513; *Nucleosides and Nucleotides*, 18 (1999) 1443). This method has several advantages over the solution-phase strategies. One advantage is that an excess of one component (e.g. peptide) can be used to drive the reaction to completion and the excess unconjugated peptide can then be removed by simple filtration and washing. This simplifies and aids the product purification following conjugation.

10

A highly efficient and generally applicable conjugation reaction is essential to success for both solution phase and solid-phase fragment coupling. Conjugation yields on solid phase may be greatly affected by the nature of the coupling component loaded onto the support and the nature of the coupling component in solution. Both components need to be maintained in high solvation and this needs a method of conjugation that allows the solvation conditions to be varied as appropriate (for example aqueous, aqueous-organic mixture, aqueous in the presence of denaturing agents etc).

A recent method used for the synthesis of large peptides and small proteins involves "native ligation" of two largely unprotected peptide fragments (Dawson *et al.*, *Science*, 266 (1994) 776; Wilken *et al.*, *Curr. Opin. Biotech.*, 9 (1998) 412), one containing a C-terminal thioester and the other an N-terminal cysteine.

In the case of peptide-oligonucleotide conjugations, Bruick *et al.* (*Chem. & Biol.*, 3 (1996) 49) have reported the ligation of a 3'-amino oligonucleotide to a peptide thio-ester oligonucleotide aligned on a DNA template, but the synthesis of the various components is cumbersome and the method is restricted to 3'-peptide conjugated oligonucleotides and requires a DNA template.

Consequently, there is a need to develop methods for coupling molecules such as peptides and oligonucleotides which is applicable to a wide range of substrates.

It is an object of this invention to provide a method of coupling molecules such as peptides and oligonucleotides using coupling chemistry which is both highly efficient and widely applicable. It is a further object of this invention to provide a method of coupling

5 molecules such as peptides and oligonucleotides which can be used in solution and on solid phase and under a wide range solvent conditions that maintain solvation of the components. It is yet a further object of this invention to provide methods and reagents for modifying molecules such as peptides and oligonucleotides in order that they can be coupled together.

10


In accordance with the present invention there is provided a method of linking a first molecule $M^1\text{-NH}_2$ with a second molecule $M^2\text{-OH}$ comprising reaction of a compound of formula (I)



wherein M^1 is the residue of a molecule bearing an amino group,
 A is an alkylene or arylene group,
 R^1 is alkyl or aryl,

20

with a compound of formula (II)



wherein M^2 is the residue of a molecule bearing a hydroxy group
 B is a linker
 D is a C_{1-4} alkylene group or C_{3-12} arylene group
 R^2 is hydrogen or a thiol protecting group.

30

The method of the present invention is of general applicability to the coupling of molecules bearing an amino group to molecules bearing a hydroxy group. Accordingly, M^1 may be the residue of any molecule bearing an amino group and M^2 may be the residue of any molecule bearing a hydroxy group. More particularly, M^1 and M^2 may each independently comprise a peptide or oligonucleotide residue. Preferably, M^1 comprises a peptide residue. Preferably, M^2 comprises an oligonucleotide residue.

As used herein the term "peptide" refers to a molecule of up to 500 amino acid or peptoid units. The amino acids may be naturally occurring, modified or synthetic amino acids. The peptide may be fully protected, partially protected or unprotected.

As used herein the term "oligonucleotide" refers to a molecule of up to 500 nucleotide units. The nucleotide units may be naturally occurring, modified or synthetic nucleotides or peptide nucleic acids (PNAs). The oligonucleotide may contain one or more chemically modified phosphate residue(s) (e.g. thiophosphate and the like) and non-phosphorus backbone substitutions (e.g. carboxamide and the like). The oligonucleotide may be fully protected, partially protected or fully unprotected.

As used herein, the term "alkyl" means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where acyclic, the alkyl group is preferably a C_1 to C_{18} , more preferably C_1 to C_{10} , more preferably C_1 to C_4 chain. Where cyclic, the alkyl group is preferably a C_3 to C_{12} , more preferably C_5 to C_{10} and more preferably C_5 , C_6 or C_7 ring. The alkyl chain or ring may include (i.e. be optionally interrupted with and/or terminate with) one or more heteroatoms, such as oxygen, sulfur or nitrogen.

As used herein the term "alkylene" means a branched or unbranched, cyclic or acyclic, saturated or unsaturated divalent hydrocarbyl radical. Where acyclic the alkylene group is preferably a C_1 to C_{18} , more preferably C_1 to C_{10} , more preferably C_1 to C_4 chain. Where cyclic, the alkylene group is preferably a C_3 to C_{12} , more preferably C_5 to C_{10} , more

preferably C₅, C₆ or C₇ ring. The alkylene chain or ring may include (i.e. be interrupted and/or terminate with) one or more heteroatoms such as oxygen, sulfur or nitrogen.

As used herein, the term "aryl" means a C₃ to C₂₆, preferably C₃ to C₁₂, aromatic group, such as phenyl or naphthyl, or a heteroaromatic group containing one or more, preferably one, heteroatom, such as pyridyl, pyrrolyl, furanyl, thienyl.

As used herein the term "arylene" means a divalent hydrocarbyl radical comprising a C₃ to C₂₆, preferably C₃ to C₁₂, aromatic group (such as o-, m- or p-phenylene) or heteroaromatic group containing one or more, preferably one, heteroatom (such as a pyridine-2,3-diyl group).

The alkyl, aryl, alkylene and arylene groups may be further substituted or unsubstituted. For example, a C₁ (methyl) group may be further substituted with a phenyl group to give a benzyl group. Substituents may include:

carbon containing groups such as

alkyl, aryl,

aralkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl);

halogen atoms and halogen containing groups such as

haloalkyl (e.g. trifluoromethyl);

oxygen containing groups such as

alcohols (e.g. hydroxy, hydroxyalkyl, aryl(hydroxy)alkyl),

ethers (e.g. alkoxy, alkoxyalkyl, aryloxyalkyl),

aldehydes (e.g. carboxaldehyde),

ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl)

acids (e.g. carboxy, carboxyalkyl),

acid derivatives such as esters

(e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl)

- and amides
(e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl);
- 5 and carbamates
(eg. alkoxycarbonylamino, aryloxy carbonylamino, aminocarbonyloxy, mono- or dialkylaminocarbonyloxy, arylaminocarbonyloxy),
- and ureas
10 (eg. mono- or dialkylaminocarbonylamino or arylaminocarbonylamino);
- nitrogen containing groups such as
amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl),
- 15 azides,
nitriles (e.g. cyano, cyanoalkyl),
nitro;
- sulfur containing groups such as
thiols, thioethers, sulfoxides, and sulfones
20 (e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl);
- and heterocyclic groups containing one or more, preferably one, heteroatom,
25 (e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl,
- 30 piperidyl, piperazinyl, morpholinyl, thianaphthyl, benzofuranyl, isobenzofuranyl, indolyl, oxyindolyl,

isoindolyl, indazolyl, indolyl, 7-azaindolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolinyl, isoquinolinyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxalinyl, chromenyl, chromanyl, isochromanyl, phthalazinyl and carbolinyl).

5

As used herein, the term "alkoxy" means alkyl-O- and "alkanoyl" means alkyl-CO. Alkyl substituent groups or alkyl-containing substituent groups may comprise one or more
10 further substituents.

As used herein, the term "aryloxy" means aryl -O- and "aryloyl" means aryl -CO. Aryl substituent groups or aryl-containing substituent groups may comprise one or more
15 further substituents.

15

As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.

According to a further aspect of the present invention there is provided a chemical
20 compound of formula (I). The compound of formula (I) is suitable for use in a method of coupling M^1 -NH₂ with M^2 -OH. Preferably, M^1 comprises a peptide residue. When M^1 is a peptide residue, the amino group in M^1 -NH₂ may be an N-terminal amino group, an internal amino group or it may be an amino group introduced at the C-terminal end of the peptide. Preferably, the amino group is an N-terminal amino group.

25

The peptide residue may be attached to a solid support. When the peptide residue is attached to a solid support, the solid support may be attached to the C-terminus, internally, or the N-terminus of the peptide residue. Preferably, the solid support is attached via the C-terminus of the peptide residue.

30

The compounds of the present invention may be prepared, and the methods of the present invention carried out, in solution phase or on a solid support, preferably on a solid support.

As used herein, the term "solid support" may be a solid support of any suitable type which will be readily apparent to those skilled in the art. Some examples of the solid supports which may be used in the present invention are polystyrene based resin such as polystyrene-co-divinylbenzene resins, polyacrylamide based resin such as PEGA resin, polyethylene glycol grafted polystyrene resin such as Tentagel® resin, PEG-PS resin and NovaGel™ resin, polyethylene/polypropylene based support such as functionalised polyethylene/polypropylene pins and crowns, or silica based support such as controlled pore glass (CPG). Preferably, the solid support used for attachment to the peptide residue is PAL-PEG-PS or NovaGel™ resin.

In an alternative embodiment, $M^1\text{-NH}_2$ comprises a peptide residue modified by introduction of an amino group at its C-terminus (by, for example, reaction of the C-terminal carboxyl group with a diaminoalkylene linker, optionally linked to a solid support, generating peptide C-terminal aminoalkylamide upon deprotection (see, for example, Breipohl et al., Tetrahedron Lett., 28 (1987) 5647).

In a further alternative embodiment, $M^1\text{-NH}_2$ may comprise an oligonucleotide residue which has been modified to incorporate an amino function. For example, an amino group may be introduced via an alkylene or arylene linker and phosphate or other group bonded via an oligonucleotide hydroxyl function (such as the 5' or 3' hydroxyl). Additionally, the oligonucleotide may be linked to a solid support. Such an approach is exemplified in Nelson et al, Nucl. Acids Res., 17 (1989) 7179; Wachter et al, Nucl. Acids Res., 14 (1986) 7985; Agrawal et al, Nucl. Acids Res., 14 (1986) 6227. Additionally, the oligonucleotide may be linked to a solid support featuring built-in amino group liberated upon deprotection (Nelson et al, Nucl. Acids Res., 17 (1989) 7187; Nelson et al, Nucl. Acids Res., 20 (1992) 6253).

In the present invention A comprises an alkylene or arylene group as defined above. Preferably A comprises a C₁₋₁₈ alkylene group, more preferably a C₂₋₄ alkylene group, more preferably an ethylene or n-propylene group.

5 R¹ may comprise an alkyl or aryl group as defined above. Preferably, R¹ comprises a C₁₋₁₈ alkyl or C₃₋₁₀ aryl group. More preferably, the compounds of formula (I) are selected from compounds in which R¹ is t-butyl, benzyl, substituted benzyl, phenyl, substituted phenyl, 2-pyridyl, 4-pyridyl, cyanomethyl, carboxamidomethyl, 2-carboxamidoethyl or trifluoroethyl. Most preferably R¹ is benzyl.

10

It will be readily apparent to the skilled person that the reactivity of the thioester can be modified by varying R¹. For instance, the compound where R¹ is phenyl will be generally more reactive than the compound where R¹ is benzyl. Furthermore, the thioester of compound (I) may be transesterified *in situ* during the coupling reaction with the molecule
15 of formula (II). The thioester may be transesterified by, for instance, thiophenol in the solvent.

In an alternative embodiment, R¹ further comprises a solid support. It will be appreciated that provision of a solid support permits solid phase synthesis or modification of the
20 molecule of formula (I) by, for example, chain elongation of the peptide residue M¹ by conventional solid phase peptide synthesis techniques.

According to a further aspect of the present invention there is provided a chemical compound of formula (II). The compound of formula (II) is suitable for use in a method of
25 coupling M¹-NH₂ with M²-OH.

Preferably M² comprises an oligonucleotide residue. When M² is an oligonucleotide residue, the hydroxy group in M²-OH may be a 5'-terminal hydroxy group, a 3'-terminal hydroxy group or another suitable internal hydroxy group. Preferably the oligonucleotide
30 is bonded via its 5'-OH terminus.

The oligonucleotide residue may be attached to a solid support, as hereinabove defined. When the oligonucleotide residue is attached to a solid support, it may be attached via its 3'-OH terminus, internally or via its 5'-OH terminus. Preferably, when the oligonucleotide residue is part of molecule (II), it is attached via its 3'-OH terminus to a solid support such as controlled pore glass or polyoxyethylene-polystyrene co-polymer.

The group B may comprise any suitable linker. Preferably, group B comprises a group of the formula:-




10

wherein J is an alkylene or arylene group and X is the residue of a functional group capable of reacting with a hydroxy group.

Preferably, J is a C₁₋₁₈ alkylene or C₃₋₁₂ arylene group, J may be functionalised, preferred functionalisation including carboxamido, urethane or sulfonamido groups. Preferably, J comprises a moiety derived from trans-4-aminocyclohexanol or 4-hydroxypiperidine.

X may be the residue of any suitable group capable of reacting with the hydroxyl function present M²-OH. Preferably, X is a phosphate (including phosphoramidate), thiophosphate (including thiophosphoramidate), phosphonate or phosphite (including phosphoramidite, thiophosphite and thiophosphoramidite) residue. In case of hydrogen phosphonate and phosphite residue, it may be optionally oxidized, e.g. by aqueous iodine solution, t-butylhydroperoxide and the like (Letsinger et al, J. Am. Chem. Soc., 97 (1975) 3278), sulfurized, e.g. using molecular sulfur solution or any suitable thionating reagent (Stec et al, J. Am. Chem. Soc., 106 (1984) 6077), or aminated, e.g. by amine - carbon tetrachloride solution (Froehler, Tet. Let., 27 (1986) 5575). More preferably X comprises a group selected from



wherein R^3 is selected from hydroxy, oxy anion and salts thereof, alkyl alkoxy, aryloxy, thiol, thioxy anion and salts thereof, S-alkyl, S-aryl, dialkylamino and N-azolyl groups.

-
- 5 Preferably R^3 is selected from hydroxy, oxyanion and salts thereof, alkyl (such as methyl and substituted methyl) methoxy, ethoxy and substituted ethoxy (such as 2-cyano ethoxy, 2-nitrophenylethoxy and 4-nitrophenylethoxy), allyloxy and substituted allyl, propargyloxy and substituted propargyl, benzyloxy and substituted benzyl, O-9-fluorenylmethyl, propyloxy and substituted propyloxy (such as 1,1,1,3,3,3 hexafluoroisopropyloxy),
 10 dimethylamino, diethylamino, methylethylamino, methylisopropylamino, ethylisopropylamino, diisopropylamino, di-n-propylamino, di-n-butylamino, diisobutylamino, dicyclohexylamino, pyrrolidino, piperidino, 2,6-dimethylpiperidino, 2,2,6,6-tetramethylpiperidino, morpholino, 2,6-dimethylmorpholino, hexamethyleneamino, heptamethyleneamino, N-imidazolyl, substituted imidazolyl, N-benzotriazolyl, N-1,2,4-
 15 triazolyl, substituted triazolyl, N-tetrazolyl, substituted tetrazolyl, 2-chlorophenoxy, 4-chlorophenoxy, 2-nitrophenoxy, 4-nitrophenoxy, pentafluorophenoxy, 1-benzotriazolyl, thiol, thioxyanion and salts thereof, S-t-butyl, S-phenyl, S-2,4-dichlorobenzyl, or S-2,4-dinitrobenzyl.
- 20 Preferably R^3 is 2-cyanoethoxy.

- D may be a C_1 to C_4 alkylene group or C_3 to C_{12} arylene group. In accordance with the definition of alkylene and arylene groups above, the groups may include one or more heteroatoms and/or heteroatomic groups such as oxygen, sulfur, nitrogen, carboxamido and
 25 the like. Preferably D is a methylene or ethylene group.

R^2 may be hydrogen or a thiol protecting group. Preferably, R^2 is selected from hydrogen, alkyl, S-alkylsulfenyl, S-arylsulfenyl, alkylcarboxamidoalkyl, alkoxycarbonyl and acyl groups.

Preferably R^2 is hydrogen, 9-fluorenylmethyl, 2-(2,4-dinitrophenyl)ethyl, t-butyl, 1-adamantyl, benzyl, substituted benzyl, benzhydryl, triarylmethyl, ethylsulfenyl, t-butylsulfenyl, tritylsulfenyl, 2-nitrobenzenesulfenyl, 2,4-dinitrobenzenesulfenyl, 3-nitro-2-pyridinesulfenyl, acetamidoemethyl, trimethyl acetamidomethyl, benzamidomethyl, benzyloxycarbonyl, acetyl or benzoyl. Most preferably, R^2 is hydrogen, t-butylsulfenyl, trityl or 4-methoxytrityl.

When R^2 is other than hydrogen, the thiol group may be unmasked *in situ* during the coupling reaction with the molecule of formula (I). The *in situ* deprotection conditions will be readily apparent to the skilled person. For instance, when R^2 is t-butylsulfenyl, the thiol group can be unmasked by reductive cleavage of the disulfide bond using tris-(2-carboxyethyl)phosphine (TCEP) dithiothreitol (DTT) or other suitable reducing agent.

In a further aspect of the present invention there is provided a compound of formula II in which the amino group is protected. Any suitable protecting group R^4 may be used. Preferably, the protecting group R^4 is selected from urethanyl, alkyl, alkylsulfenyl, arylsulfenyl and sulphonyl protection groups.

Preferably R^4 is 9-fluorenylmethoxycarbonyl, allyloxycarbonyl, propargyloxycarbonyl, t-butyloxycarbonyl, benzyloxycarbonyl, 2-(2-nitrophenyl)ethoxycarbonyl, 2-(4-nitrophenyl)ethoxycarbonyl, 2-(2,4-dinitrophenyl)ethoxycarbonyl, heteroarylmethoxycarbonyl, diarylmethyl, triarylmethyl, trityl, 2,6-dioxocyclohexyliden-1-ylmethyl, substituted 2,6-dioxocyclohexyliden-1-ylmethyl, 2-nitrobenzenesulfenyl, 2,4-dinitrobenzenesulfenyl, 3-nitro-2-pyridinesulfenyl, substituted arenesulfonyl, 2-nitrobenzenesulfonyl, 2,4-dinitrobenzenesulfonyl. Most preferably, R^4 is 9-fluorenylmethoxycarbonyl.

When R^4 is other than hydrogen, the amino group may be unmasked *in situ* during the coupling reaction with the molecule of formula (I). The *in situ* deprotection conditions will be readily apparent to the skilled person. For instance, when R^4 is, 9-

fluorenylmethoxycarbonyl (Fmoc), the amino group can be unmasked under mildly basic conditions such as 20% (v/v) pyridine in dimethylformamide.

5 Either of the compound of formula (I) or (II), but not both, may be attached to a solid support during the coupling reaction. The resultant conjugate may be cleaved from the solid support by methods known in the art.

Alternatively, the coupling of molecules (I) and (II) may be performed in solution. The solution may be either aqueous or non-aqueous, or may comprise a mixture of aqueous and
10 non-aqueous solvents with or without denaturing agent such as urea or guanidinium chloride. The solution may optionally be buffered with a suitable buffer. The solution may optionally comprise, reagent(s) for the transesterification of the thioester in molecule (I), e.g. thiophenol, and/or reagent(s) for the deprotection of the thiol group in molecule (II), e.g. TCEP.

15

According to a further aspect of the present invention there is provided a chemical compound of formula (III) and its use in a method of producing a compound of formula (I) by reaction with M^1-NH_2 .

20 $R^5-CO-A-CO-SR^1$ (III)

wherein A and R^1 are as previously defined, and

R^5 is selected from hydroxy, oxy anion and salts thereof, alkoxy, aryloxy N-succinimidyl, N-(norbornenedicarboximido)oxy, N-benzotriazolyl, N-(1,2-dihydro-1-oxo-2,3,4-benzotriazin-2-yl)oxy, halogen and N-azolyl groups; or
25 together with the adjacent CO group forms an anhydride.


Preferably, R^5 is selected from the group consisting of hydroxy, oxy anion and salts thereof, alkoxy (such as 2-cyanoethoxy), substituted or unsubstituted aryloxy (such as 2-nitrophenoxy, 4-nitrophenoxy, 2,4,5-trichlorophenoxy, pentachlorophenoxy, 2,3,5,6-tetrafluorophenoxy and pentafluorophenoxy), substituted or unsubstituted N-
30

(succinimidyl)oxy (such as N-(2-sulfosuccinimidyl)oxy (which is particularly preferred as it improves solubility and maintains reactivity in aqueous and aqueous-organic solutions) and N-(norbornenedicarboximido)oxy, N-(benzotriazolyl)oxy, substituted N-(benzotriazolyl)oxy (such as N-(7-azabenzotriazdyl)oxy, N-(1,2-dihydro-1-oxo-2,3,4-benzotriazin-2-yl)oxy, substituted N-(1,2-dihydro-1-oxo-2,3,4-benzotriazin-2-yl)oxy, halogen (such as fluorine and chlorine), N-azolyl groups (such as N-imidazolyl and substituted imidazolyl, N-benzotriazolyl, N-1,2,4-triazolyl, substituted triazolyl, N-tetrazolyl, substituted tetrazolyl and azido); or together with the adjacent CO group forms a symmetrical anhydride, or a mixed anhydride with carboxylic acids (such as trimethylacetic, 1-adamantane carboxylic or isovaleric), carbonic acid phosphoric or thiophosphoric acids (such as dimethylphosphoric, diethylphosphoric or diphenylphosphoric acids), phosphonic acids (such as n-propylphosphonic acid), phosphinic or thiophosphinic acids (such as dimethylphosphinic, dimethyl thiophosphinic, diphenylphosphinic or diphenylthiophosphinic acids), sulfonic acids (such as benzene and substituted benzene sulfonic acids, methane sulfonic acid, trifluoromethane-sulfonic acid, trifluoroethane sulfonic acid and polymeric poly (fluorocarbon) sulfonic acid) or hydrocyanic acid.

The reaction between a coupling reagent of formula (III) and the amino group of a peptide residue or an amino-modified oligonucleotide residue will chemoselectively form an amide bond between the amino group and the coupling reagent (III) by overall displacement of R^5 . Accordingly, R^5 should be chosen such that the adjacent carbonyl is more reactive to amino groups than the carbonyl of the thioester. The choice of R^1 and R^5 to achieve the desired chemoselectivity will be readily apparent the skilled person. The choice of R^5 is also influenced by the intended medium for the reaction with M^1-NH_2 . For example when M^1 is a peptide residue selection of R^5 as an N-succinimidyl group (such as N-(2-sulfosuccinimidyl)oxy) is particularly preferred as it improves solubility in aqueous-organic mixtures. In non-aqueous media, R^5 is preferably pentafluorophenoxy while R^1 is benzyl.

The preparation and coupling of molecules of general formulae (I) and (II) is exemplified in Reaction Scheme 1. It will be appreciated that preparation and coupling of molecules of general formula (I) and (II) may be carried out by modification of the procedures shown in Reaction Scheme 1 in accordance with conventional synthetic organic chemistry.

5




15

Reaction Scheme 1

20

According to a further aspect of the present invention there is provided a chemical compound of formula (IV) and its use in producing a compound of formula (II) by reaction with M^{2+} -OH.

25



wherein D, J, R^2 , R^3 and R^4 are as previously defined; and R^6 is selected from
 30 dialkylamino (such as dimethylamino, diethylamino, methylethylamino, methylisopropylamino, ethylisopropylamino, diisopropylamino di-n-propylamino, di-n-

butylamino, diisobutylamino, dicydonexylamino, pyrrolideno, piperidino, 2,6-demethylpiperidino, 2,2,6,6-tetramethyl-piperidino, morpholino and 2,6-dimethylmorpholino); imino (such as hexamethylene imino and heptamethylene imino); halogen (such as fluorine and chlorine); N-azolyl (such as N-imidazolyl and substituted imidazolyl, N-benzotriazolyl, N-1,2,4-triazolyl and substituted triazolyl, N-tetrazolyl and substituted N-tetrazolyl); alkoxy (such as 1,1,1,3,3,3-hexafluoroisopropoxy); aryloxy (such as 2-nitrophenoxy, 4-nitrophenoxy, pentafluorophenoxy, 1-benzotriazolylloxy); alkylthio (such as S-tert-butyl) and arylthio (such as S-phenyl). Preferably R^6 is a dialkylamino group, more preferably a diisopropylamino group.


10

The group represented by R^6 on the coupling reagent (IV) will be displaced by a nucleophilic hydroxy group in M^2 -OH (such as an oligonucleotide hydroxy residue) to form the molecule represented by the formula (II). Preferably, the nucleophilic group is the 5'-OH terminus of the oligonucleotide residue.


15

The coupling reagents (III) and (IV) may be prepared by procedures such as those described in Reaction Schemes 2 and 3. It will be appreciated that coupling reagents of general formulae (III) and (IV) may be prepared by modification of the procedures shown in reaction schemes 1 and 2 in accordance with conventional synthetic organic chemistry.

20




Reaction Scheme 2: Synthesis of coupling reagent (III)



Reaction Scheme 3: Syntheses of coupling reagent (IV)


According to the present invention the coupling reaction provides a chemical compound comprising a structural unit of formula (V)



wherein A, B and D are as defined above.

More particularly, there is provided a chemical compound of the formula (VI)

10




wherein M^1 , M^2 , A, B and D are as defined above.

15

Where M^1 and M^2 are peptide and oligonucleotide residues respectively, such compounds may have therapeutic utility. For example, the peptide residue may facilitate cellular uptake or intracellular activity of a therapeutic oligonucleotide. The peptide may act as a signal molecule for identification of the location of the oligonucleotide within a cell or for
20 the delivery of the oligonucleotide to a specific cellular location or may enhance the targeting ability of the oligonucleotide towards cellular RNA or DNA in an antisense or triplex therapeutic or diagnostic application.

The thiol group of the compound of formula (VI) is particularly suited to further
25 derivatisation or functionalisation and can, for example, provide a site for attachment of a labelling, reporter or effector group. Accordingly, the invention further provides a chemical compound of the formula (VII)



wherein M^1 , M^2 , A, B and D are as defined above, and Y is a labelling, reporter or effector group.

- 5 The invention will now be described in detail with reference to the following examples. It will be appreciated that this invention is described by way of example only and modification of detail may be made without departing from the scope of the invention.

10 **Example 1: Preparation of Coupling Reagent (III)**

1) S-Benzyl thiosuccinic acid. Benzyl mercaptane (22 mmol, 2,595 ml) was added under nitrogen to stirred solution of succinic anhydride (20 mmol, 2,0014 g) and 4-dimethylaminopyridine (1 mmol, 122.2 mg) in 25 ml of anhydrous acetonitrile – pyridine
 15 (9:1 v/v). Stirring was continued at room temperature for 3 h, evaporated to near dryness, redissolved in sodium bicarbonate solution, pH 8.5, and extracted twice with diethyl ether. Water phase was then cooled at ice bath, acidified with 5N hydrochloric acid to pH 2, white precipitate filtered, washed with ice-cold water and dried in vacuum desiccator over phosphorus pentoxide overnight. Yield of white powder 3.5985 g (80%). $^1\text{H-NMR}$ (CDCl_3 ,
 20 δ , ppm): 7.29-7.26 (m, 5H, Ph), 4.16 (s, 2H, CH_2S), 2.94-2.90 (t, 2H, CH_2COS), 2.77-2.72 (t, 2H, $\text{CH}_2\text{CO}_2\text{H}$).

2) Pentafluorophenyl S-benzyl thiosuccinate. Solution of dicyclohexylcarbodiimide (11 mmol, 2.2696 g) in 15 ml of dichloromethane was added dropwise to stirred and cooled
 25 (ice bath) solution of S-benzyl thiosuccinic acid (2.243 g, 10 mmol) and pentafluorophenol (11.5 mmol, 2.117 g) in 25 ml of dichloromethane. Reaction mixture was stirred for 0.5 h on ice bath, then allowed to warm slowly to room temperature, stirred for 4 h and left overnight in a fridge. Dicyclohexylurea precipitate was filtered (2.148 g, 96% yield), solution concentrated in vacuo, redissolved in minimal volume of ethylacetate, filtered
 30 again, and hexane was added. After standing overnight in a freezer, crystals were filtered, washed with cold ethylacetate - hexane (1:9 v/v) and dried in vacuo overnight. Yield of

white needles 3.4376 g (88%). After evaporating of mother liquor and further treatment with hexane additional 0.183 g of title compound could be obtained. Total yield of two crops 3.6206 g (92%). $^1\text{H-NMR}$ (CDCl_3 , δ , ppm): 7.30-7.27 (m, 5H, Ph), 4.18 (s, 2H, CH_2S), 3.05 (s, 4H, CH_2CH_2).

5

Example 2: Preparation of Coupling Reagent (IV)

1). N-Fmoc-S-trityl-L-cysteine 4-hydroxypiperidide. 4-Hydroxypiperidine (2.3 mmol, 232.6 mg) was added with stirring to the solution of N-Fmoc-S-trityl-L-cysteine pentafluorophenyl ester (2 mmol, 1.504 g) in 25 ml of anhydrous acetonitrile, followed by triethylamine (0.5 mmol, 0.07 ml). Reaction mixture was stirred at room temperature for 4 h, until TLC revealed the reaction completed. The mixture was then evaporated to dryness, redissolved in ethylacetate and washed successively with ice-cold 5% wt. citric acid, water, sodium bicarbonate and brine, dried over sodium sulfate, and evaporated to a light brown
15 foam. The residue was chromatographed on silica gel column eluted by 15-30% of acetonitrile in chloroform, appropriate fractions were pooled and evaporated to give 1.3126 g (98%) of the title product as a white foam.

2). N-Fmoc-S-trityl-L-cysteine 4-hydroxy-trans-cyclohexylamide. To the slurry of *trans*-4-aminocyclohexanol hydrochloride (2.1 mmol, 318.4 mg) and N-Fmoc-S-trityl-L-cysteine pentafluorophenyl ester (2 mmol, 1.504 g) in 25 ml of anhydrous DMF triethylamine was
20 added (2.2 mmol, 0.307 ml), and resulting solution was stirred at room temperature for 3 h, until TLC revealed reaction completed. Reaction mixture was then evaporated to dryness, redissolved in ethylacetate and washed successively with ice-cold 5% wt. citric acid, water, sodium bicarbonate and brine, dried over sodium sulfate, and evaporated to a light brown
25 foam. The residue was chromatographed on silica gel column eluted by 15-5% hexane in ethylacetate – 0.5% triethylamine, appropriate fractions were pooled and evaporated to give 1.3045 g (95%) of the title product as a white foam.

3). N-Fmoc-S-*tert*-butylsulfenyl-L-cysteine 4-hydroxy-trans-cyclohexylamide. To the slurry of *trans*-4-aminocyclohexanol hydrochloride (2 mmol, 303.3 mg) and N-Fmoc-S-*tert*-butylsulfenyl-L-cysteine pentafluorophenyl ester (2 mmol, 1.195 g) and 1-
30 hydroxybenzotriazole (2 mmol, 270.3 mg) in 20 ml of anhydrous DMF, triethylamine was

added (3.1 mmol, 0.446 ml), and resulting solution was stirred at room temperature for 3 h, until TLC revealed reaction completed. Reaction mixture was then evaporated to dryness, white residue transferred to sintered glass filter, washed successively with small amount of DMF, ethanol and diethyl ether, and dried in vacuo. Yield of white powder 0.868 g (82%).

5 4). N-Fmoc-S-*tert*-butylsulfenyl-L-cysteine 4-hydroxypiperidide. 4-Hydroxypiperidine (2.5 mmol, 253.1 mg) was added with stirring to the solution of N-Fmoc-S-*tert*-butylsulfenyl-L-cysteine pentafluorophenyl ester (2 mmol, 1.195 g) in 20 ml of anhydrous DMF. Reaction mixture was stirred for 3 h at room temperature until TLC revealed completed reaction. The mixture was then evaporated to dryness, redissolved in
10 ethylacetate and washed successively with 5% wt. citric acid, water, sodium bicarbonate and brine, dried over sodium sulfate, and evaporated to a light yellow foam. The residue was chromatographed on silica gel column eluted by 10-0% hexane in ethylacetate, appropriate fractions were pooled and evaporated to give 0.9831 g (95%) of the title product as a white foam.

15 5). 4-*trans*-N-Fmoc-S-trityl-L-cysteinylamidocyclohexyl 2-cyanoethyl N,N-diisopropyl phosphoramidite. To a solution of N-Fmoc-S-trityl-L-cysteine 4-hydroxy-*trans*-cyclohexylamide (0.3444 mmol, 0.2352 g) in 10 ml of anhydrous dichloromethane containing 75 mg (1.5 eq) of diisopropylammonium tetrazolate, 2-cyanoethoxy-N,N,N',N'-tetraisopropyl phosphordiamidite (1.15 eq, 0.126 ml) was added, and the
20 mixture was stirred for 6 h at room temperature, until TLC revealed complete conversion. Dichloromethane was then evaporated, residue taken up in ethylacetate, washed with saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and evaporated to a small volume. The rest was chromatographed on silica gel column eluted with 25-10% hexane in ethylacetate – 3% triethylamine, appropriate fractions pooled and
25 evaporated to dryness. Yield of a title product 1.3045 g (95%).

6). 4-N-Fmoc-S-trityl-L-cysteinylpiperidyl 2-cyanoethyl N,N-diisopropyl phosphoramidite. To a chilled (ice bath) solution of N-Fmoc-S-trityl-L-cysteine 4-hydroxypiperidide (0.668 g, 1 mmol) in 10 ml of anhydrous dichloromethane containing 3 mmol (0.514 ml) of diisopropylethylamine, 2-cyanoethoxy-N,N-diisopropylaminochlorophosphine (1.3 mmol, 0.29 ml) was added dropwise via syringe
30 and nitrogen. After 1 h of stirring cold, the mixture was allowed to warm up gradually,

and stirring was continued for 2 h at room temperature. The mixture was then quenched with 0.1 ml of methanol, evaporated to dryness, residue taken up in ethylacetate, washed with saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and evaporated to a small volume. The rest was chromatographed on silica gel column eluted

5 with 30-15% hexane in dichloromethane – 3% triethylamine, appropriate fractions pooled and evaporated to dryness. Yield of a title product 0.695 g (80%).

7). 4-*trans*-N-Fmoc-S-*tert*-butylsulfenyl-L-cysteinyamidocyclohexyl 2-cyanoethyl N,N-diisopropyl phosphoramidite. To a chilled (ice bath) solution of 4-*trans*-N-Fmoc-S-*tert*-butylsulfenyl-L-cysteinyamidocyclohexanol (0.834 g, 1.577 mmol) in 15 ml of anhydrous
10 dichloromethane containing 3 eq (0.785 ml) of diisopropylethylamine, 2-cyanoethoxy-N,N-diisopropylamino chlorophosphine (1.5 eq, 0.529 ml) was added dropwise via syringe under nitrogen. After 1 h of stirring cold, the mixture was allowed to warm up gradually, and stirring was continued for 2 h at room temperature. The mixture was then quenched with 0.1 ml of methanol, evaporated to dryness, residue taken up in ethylacetate, washed
15 with saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and evaporated to a small volume. The rest was chromatographed on silica gel column eluted with 25-10% hexane in ethylacetate – 2.5% triethylamine, appropriate fractions pooled and evaporated to dryness. Yield of a title product 0.7567 g (66%).

20 **Example 3: Preparation of Modified Peptide (I)**

All peptides were synthesized on the PioneerTM peptide synthesizer (PE Biosystems) on 0.1 mmol scale, by HATU/DIEA mediated in situ activation protocol supplied by manufacturer. N- α -Fmoc amino acids had standard side chain protection, respectively:
25 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl on arginine, trityl on asparagine and glutamine, t-butyl on aspartic and glutamic acids, serine, threonine and tyrosine, t-butoxycarbonyl on lysine and tryptophan, and trifluoroacetyl on lysine, were used in 4-fold excess, with no double couplings, and all were of commercial origin. Syntheses were made on either PAL-PEG-PS support (PE Biosystems) or Rink amide NovaGelTM (CN
30 Bioscience). After completion of the desired sequence and N-terminal Fmoc deprotection, the support (0.1 mmol) was transferred to a vial, and then coupling of pentafluorophenyl S-

benzylthiosuccinate was performed manually, using 4.5 eq (0.176 g) of the compound and 1 eq (14 mg) of 1-hydroxy-7-azabenzotriazole (HOAt) as a catalyst, in 2 ml of a freshly distilled DMF for 4 h at room temperature. The resin was then washed with 5x4 ml of DMF, 5x3 ml of methanol, and 5x2 ml of diethyl ether, and dried in vacuo. The N-

5 modified peptide was cleaved from the resin and deprotected, using 6 ml of trifluoroacetic acid – benzyl mercaptan – phenol – water (90:5:2.5:2.5 v/v/v/v) cocktail, for 2-6 h at room temperature, depending on arginine content. The resin was filtered, washed with 5x4 ml of TFA, the volume was reduced to cal. 1-2 ml by purging nitrogen, and 40 ml of cold diethyl

10 ether was then added to precipitate the peptide. The slurry was centrifugated, ether decanted, and procedure was repeated three times to remove scavengers. The peptide pellet was then dried in vacuo, dissolved in 0.1% aqueous TFA/acetonitrile mixture, and subjected to RP HPLC purification on a C₈ column by a gradient of an acetonitrile in 0.1% aqueous TFA. The appropriate fractions were lyophilised and analysed by MALDI-TOF MS, using α -cyano-4-hydroxy cinnamic acid as a matrix. Typical examples are given in

15 **Table 1.**

Table 1. Automated solid phase synthesis of peptide N-terminal S-benzyl thioesters.

Sequence	MALDI-TOF MS	Purity of crude product, % (HPLC)
BnSCO-RQIPK ¹¹⁸ IWFPNRRK ¹¹⁸ PFK ¹¹⁸ K ¹¹⁸ -CONH ₂	2714.59	72.0
BnSCO-GRK ¹¹⁸ K ¹¹⁸ RRQRRR-CONH ₂	1791.63	76.5
BnSCO-PTSQSRGDPTGPKE-CONH ₂	1660.25	88.7
BnSCO-DRVIEVVQGAYRAIRNIPRRIRQG-CONH ₂	3040.62	28.6
BnSCO-QAKKKKLDK-CONH ₂	1289.92	90.3
BnSCO-ALPPLERLTL-CONH ₂	1325.70	74.7
BnSCO-GALFLGFLGAAGSTMGAWSQPKSKRKV-CONH ₂	2969.05	48.3

Example 4: Preparation of Modified Oligonucleotide (II)

20

Oligonucleotides were synthesized on ABI 380B automated DNA/RNA synthesizer (PE Biosystems) on 1 μ mol scale. Standard 3'-nucleoside succinate LCAA-CPG 500A supports were used. After completion of the assembly of the desired sequence and 5'-

terminal 4,4'-dimethoxytrityl (Dmt) group cleavage by 2% dichloroacetic acid solution in dichloromethane (v/v), support-bound oligonucleotide was treated on machine with 0.15M solution of modified phosphoramidite reagent (t-butylsulfenyl or trityl S-protected) in anhydrous acetonitrile mixed with 0.5M solution of 1*H*-tetrazole in anhydrous acetonitrile, for 10 min at room temperature. The support was then washed with standard oxidizing solution (0.1M iodine in aqueous pyridine – tetrahydrofuran), washed with acetonitrile and dried. Fmoc amino protecting group can be selectively removed from support-bound oligonucleotide by treating the support with 20% piperidine solution in dimethylformamide (v/v) for 15 min at room temperature. S-Trityl protecting group can be selectively removed on solid support with 0.05M aqueous solution of silver nitrate for 15 min, followed by 0.05M dithiothreitol (DTT) for 5 min (Mag et al, Nucl. Acids Res., 19 (1991) 1437). Alternatively, S-Trt protection can be removed in solution with silver nitrate as well (Connolly and Rider, Nucl. Acids Res., 13 (1985) 4485). S-t-Butylsulfenyl group is also sufficiently stable to concentrated aqueous ammonia deprotection at 55°C routinely employed in oligonucleotide synthesis to allow isolation of S-t-butylsulfenyl-protected oligonucleotides, which may be subsequently deprotected by treating with 0.1M aqueous solution of tris-(2-carboxyethyl)phosphine, pH 7.0, at room temperature overnight. Both S-trityl and S-t-butylsulfenyl provide convenient hydrophobic handles for reverse phase purification of synthesized oligonucleotides. Routinely, S-protected cysteine-modified oligonucleotides were isolated after RP HPLC on μ Bondapak C₁₈ column eluted by a gradient of an acetonitrile in 0.1M aqueous ammonium or triethylammonium acetate solution, pH 7.0, desalted on Sephadex G-10 or G-25 column, lyophilised and analysed by MALDI-TOF MS using 2,6-dihydroxyacetophenone – ammonium citrate as matrix. Typical examples are given in Table 2.

25

Table 2. Automated solid phase synthesis of 5'-cysteinyl oligonucleotides.

Sequence	MALDI-TOF MS	Purity of crude product, % (HPLC)
Cys(SBu ^t)-TTT TT	1825.13	87.1
Cys(Trt)-TTT TT	1983.16	76.6
Cys-TTT TT	1738.24	82.2

Cys(SBu ^t)-CTC CCA GGC TCA AAT	4874.42	82.6
Cys(SBu ^t)-GCT CCC AGG CTC AAA	4888.15	89.7
Cys(Trt)-CTC CCA GGC TCA AAT	5017.05	91.2
Cys(Trt)-GCT CCC AGG CTC AAA	5043.74	89.2
Cys(Trt)-AGC TCC CAG GCT CAA	5043.88	90.5

Example 5: Coupling Reactions (Soln phase + Solid phase)

Example 5a. 0.9 μmol of crude oligodeoxynucleotide TTT TT, 5'-modified with 4-(*S-tert*-butylsulfenyl)cysteinylamido-*trans*-cyclohexyl phosphate, were dissolved in 1 ml of 25% v/v N,N-dimethylformamide – 0.1M sodium phosphate buffer, pH 7.5, containing 7M urea and 0.1M *tris*-(2-carboxyethyl)phosphine, and 4.5 μmol of lyophilised peptide PTSQSRGDPTGPKE amide, N-terminally modified with S-benzyl thiosuccinyl moiety, were added followed by 4% v/v thiophenol. The mixture was incubated at ambient temperature for 24 h, and then analysed by RP-HPLC ($\mu\text{Bondapak C}_{18}$ analytical column, detection at 218 and 254 nm, flow rate 1 ml/min, buffer A: 0.1M ammonium acetate, pH 7.0, buffer B: acetonitrile, gradient: 5 min 2% B, 20 min 40% B, 25 min 100% B, retention time: starting *S-tert*-butyl oligonucleotide 16.608 min, reduced oligonucleotide 14.575 min, conjugate 15.258 min). After isolation by preparative HPLC, conjugate was assessed by MALDI-TOF MS: calculated 3277.59, observed 3376.72. Yield: 75% calculated on starting oligonucleotide.

Example 5b. 0.6 μmol of crude oligodeoxynucleotide GCTCCCAGGCTCAAA, 5'-modified with 4-(*S-tert*-butylsulfenyl)cysteinylamido-*trans*-cyclohexyl phosphate, were dissolved in 1 ml of 25% v/v N,N-dimethylformamide – 0.1M sodium phosphate buffer, pH 7.5, containing 0.1M *tris*-(2-carboxy ethyl)phosphine, and 3 μmol of lyophilised peptide PTSQSRGDPTGPKE amide, N-terminally modified with S-benzyl thiosuccinyl moiety, were added followed by 4% v/v thiophenol. The mixture was incubated at ambient temperature for 24 h, and then analysed by RP-HPLC ($\mu\text{Bondapak C}_{18}$ analytical column, detection at 218 and 254 nm, flow rate 1 ml/min, buffer A: 0.1M triethylammonium acetate, pH 7.0, buffer B: acetonitrile, gradient: 5 min 2% B, 20 min 40% B, 25 min 100% B, retention time: starting *S-tert*-butyl oligonucleotide 16.875 min, reduced oligonucleotide 16.083 min, disulfide oligonucleotide 24.750 min, conjugate 15.541 min, disulfide


conjugate 26.933 min). After isolation by preparative HPLC, conjugate was assessed by MALDI-TOF MS: calculated 6340.51, observed 6340.17. Yield: 65% calculated on starting oligonucleotide.

Example 5c. Solid phase oligonucleotide synthesis column with 1 μ mol of crude
 5 oligodeoxynucleotide CTCCCAGGCTCAAAT, 5'-modified with 4-(N-Fmoc-S-*tert*-butylsulfenyl)cysteinyllamido-*trans*-cyclohexyl 2-cyanoethyl phosphate, still attached to the support, was treated in syringe first with 20% piperidine in N,N-dimethylformamide (v/v) for 15 min, washed with 5 ml DMF, then with 1 ml of 0.5M solution of dithiothreitol in N,N-dimethylformamide – water (1:1 v/v) for 2 h, and washed with 10 ml DMF – water
 10 (1:1 v/v). Then 1 ml of solution of 5 μ mol of lyophilised peptide GRK^{Tfa}K^{Tfa}RRQRRR amide (Tfa – trifluoroacetyl), N-terminally modified with S-benzyl thiosuccinyl moiety, in 25% DMF – 0.1M sodium phosphate buffer, pH 7.5, containing 4% v/v thiophenol, was added via syringe. The column was incubated at ambient temperature for 24 h, and then washed with 10 ml of 25% acetonitrile – water (v/v). Then 1 ml of 0.5M iodoacetamide
 15 solution in 40% DMF – 0.1M sodium phosphate buffer, pH 7.5, was added via syringe, and the column incubated at ambient temperature for further 24 h. After washing with 10 ml of DMF – water (1:1 v/v) support was dried, transferred to screw-capped vial and treated with 25% aqueous ammonia solution at 55°C for 16 h. The glass beads were decanted, washed with 0.5 ml of 25% aqueous ammonia and 0.5 ml of water, the volume of supernatant was
 20 reduced to 250 μ l, and the mixture was then analysed by RP-HPLC (μ Bondapak C₁₈ analytical column, detection at 218 and 254 nm, flow rate 1 ml/min, buffer A: 0.1M ammonium acetate, pH 7.0, buffer B: acetonitrile, gradient: 5 min 2% B, 20 min 40% B, 25 min 100% B, retention time: starting S-*tert*-butyl oligonucleotide 15.025 min, reduced oligonucleotide 13.338 min, conjugate 14.016 min). Yield: cal. 45% by HPLC.

CLAIMS

1. A method of linking a first molecule M^1-NH_2 with a second molecule M^2-OH comprising reaction of a compound of formula (I)


5



wherein M^1 is the residue of a molecule bearing an amino group
 A is an alkylene or arylene group,
 10 R^1 is alkyl or aryl,

with a compound of formula (II)

15



M^2 is the residue of a molecule bearing a hydroxy group
 wherein B is a linker
 20 D is a C_{1-4} alkylene group or C_{3-12} arylene group
 R^2 is hydrogen or a thiol protecting group.


2. A chemical compound of formula (I) as defined in claim 1.
- 25 3. A chemical compound according to claim 2 wherein M^1 comprises a peptide residue.
4. A chemical compound according to claim 2 or 3 wherein A comprises a C_{1-4} alkylene group.
- 30 5. A chemical compound according to claim 4 wherein A comprises an ethylene ($-CH_2-CH_2-$) or n-propylene ($-CH_2-CH_2-CH_2-$) group.

6. A chemical compound according to any one of claims 2 to 5 wherein R^1 comprises a C_{1-18} alkyl or C_{3-10} aryl group.
7. A chemical compound according to claim 6 wherein R^1 is selected from the group consisting of t-butyl, substituted or unsubstituted benzyl, substituted or unsubstituted phenyl, 2-pyridyl, 4-pyridyl, cyanomethyl carboxamidomethyl, 2-carboxamidoethyl and trifluoroethyl.
8. A chemical compound of formula (II) as defined in claim 1.
9. A chemical compound according to claim 8 wherein M^2 comprises an oligonucleotide residue.
10. A chemical compound according to claim 8 or 9 wherein the linker B comprises a group of the formula

$-X-J-$

 wherein J is an alkylene or arylene group
 X is the residue of a functional group capable of reacting with a hydroxy group.
11. A chemical compound according to claim 10 wherein J is a C_{1-18} alkylene group or C_{3-12} arylene group.
12. A chemical compound according to claim 11 wherein J comprises a moiety derived from trans-4-aminocyclohexanol or 4-hydroxypiperidine.
13. A chemical compound according to any one of claims 10 to 12 wherein X is a phosphate, thiophosphate, phosphonate or phosphite residue.

14. A chemical compound according to claim 13 wherein X comprises a group selected from



5

wherein R^3 is selected from hydroxy, oxy anion and salts thereof, alkyl, alkoxy, aryloxy, thiol, thioxy anion and salts thereof, S-alkyl, S-aryl, N-azolyl, dialkyl amino groups.

10

15. A chemical compound according to claim 14 wherein R^3 is a 2-cyanoethoxy group.

16. A chemical compound according to any one of claims 8 to 15 wherein D is a methylene or ethylene group.

15

17. A chemical compound according to any one of claims 8 to 16 wherein R^2 is selected from hydrogen, alkyl, S-alkylsulfenyl, S-arylsulfenyl, alkylcarboxamidoalkyl, urethanyl and acyl groups.


- 20 18. A chemical compound according to claim 17 wherein R^2 is hydrogen tert-butyl sulfenyl or trityl.

19. A chemical compound according to any one of claims 8 to 18 wherein the amino group of the compound of formula II is protected.

25

20. A chemical compound according to claim 20 wherein the amino group is protected with a protecting group R^4 selected from urethanyl, alkyl, alkylsulfenyl, aryl sulfenyl and sulfonyl protecting groups.

- 30 21. A chemical compound of the formula (III)



wherein A and R^1 are as defined in any preceding claim


R^5 is selected from hydroxy, oxy anion and salts thereof, alkoxy, aryloxy N-succinimidyloxy, N-(norbornenedicarboximido)oxy, N-benzotriazolyloxy, N-(1,2-dihydro-1-oxo-2,3,4-benzotriazin-2-yl)oxy, halogen and N-azolyl groups; or together with the adjacent

5

CO group forms an anhydride.

22. A chemical compound according to claim 21 wherein R^5 is a pentafluorophenoxy group.

10 23. A chemical compound of the formula (IV)




15

wherein D, J, R^2 , R^3 and R^4 are as defined in any preceding claim, R^6 is selected from dialkyl amino, imino, halogen N-azolyl, alkoxy, aryloxy, alkylthio, arylthioaryl groups.

20 24. A chemical compound according to claim 23 wherein R^6 is a dialkyl amino group.

25. A chemical compound according to claim 24 wherein R^6 is a di-isopropylamino group.


25 26. A chemical compound comprising a structural unit of formula (V)



30

wherein A, B and D are as defined in any preceding claim.

27. A chemical compound according to claim 26 of the formula (VI)




wherein M^1 , M^2 , A, B and D are as defined in any preceding claim.

28. A chemical compound according to any one of claims 2 to 27 wherein the compound is linked to a solid support.

29. A method according to claim 1 wherein M^1 , M^2 , A, B, D, R^1 and R^2 are as defined in any of claims 4 to 23.

30. A chemical compound of the formula (VII)




wherein M^1 , M^2 , A, B and D are as defined in any preceding claim
Y is labelling, reporter or effector group.

31. Use of a chemical compound according to any one of claims 2 to 28 in a process for linking a peptide and an oligonucleotide.


32. A chemical compound according to claim 27 or 30 for use in therapy.

33. A method of producing a compound of formula (I) comprising reaction of a compound of the formula



with a chemical compound according to claim 21 or 22 wherein M^1 , A, R^1 and R^5 are as defined in any preceding claim.

34. A method of producing a compound of formula II comprising reaction of a
5 compound of the formula
-



- 10 with a chemical compound according to any one of claims 23 to 25 wherein M^2 , B, D, R^2 , R^3 , R^4 and R^6 are as defined in any preceding claim.

100-100000

100-100000

100-100000

100-100000
